English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduThe vast majority of people – 30.6% – who have the minimally invasive heart valve replacement procedure called TAVR do not participate in recommended cardiac rehabilitation, a study finds.
Tag: TAVR
TVT 2023 Late-Breaking Science Announced
The Cardiovascular Research Foundation (CRF) announced that TVT: The Structural Heart Summit will feature 15 Late-Breaking Clinical Science studies. An annual meeting featuring cutting-edge research and techniques for structural heart interventions, TVT will take place June 7-10, 2023, at the Phoenix Convention Center – West in Phoenix, Arizona.
TVT 2023 Program Guide Available
The program guide for TVT 2023: The Structural Heart Summit is available online. An annual meeting from the Cardiovascular Research Foundation (CRF), TVT features cutting-edge research and techniques for structural heart interventions and will take place June 7-10, 2023, at the Phoenix Convention Center – West in Phoenix, Arizona.
Atlantic Health System’s Morristown Medical Center Reaches 4,000th TAVR Procedure
Morristown Medical Center’s Gagnon Cardiovascular Institute’s structural heart program reached a significant milestone of performing over 4,000 transcatheter aortic valve replacement (TAVR) procedures with well over 650 in 2022 alone.
Hospitals without highest stroke care designation may miss them after heart procedure
Hospitals without the highest stroke care designation may be missing strokes that occur after a common heart valve replacement procedure. Investigators found that comprehensive stroke centers reported significantly greater stroke rates after transcatheter aortic valve replacement (TAVR) than hospitals without the designation.
Novel TEER Repair Device Meets Primary Endpoint in Treating Degenerative Mitral Regurgitation in Patients Not Eligible for Surgery
Results of the first randomized controlled trial to directly compare two contemporary transcatheter edge-to-edge repair (TEER) devices for degenerative mitral regurgitation (DMR) found that the PASCAL transcatheter valve repair system was non-inferior compared with MitraClip in patients with significant symptomatic DMR who are not eligible for mitral valve surgery.
Findings from the CLASP IID trial were reported today at TCT 2022, the 34th annual scientific symposium of the Cardiovascular Research Foundation (CRF). TCT is the world’s premier educational meeting specializing in interventional cardiovascular medicine.
STS/ACC TVT Registry Analysis Assesses Use of Transcatheter Edge-to-Edge Repair in Severe Mitral Regurgitation and Cardiogenic Shock
An analysis from the Society of Thoracic Surgeons/American College of Cardiology (STS/ACC) TVT Registry found that most patients with severe mitral regurgitation (MR) and cardiogenic shock (CS) who underwent mitral transcatheter edge-to-edge repair (TEER) in the United States achieved successful MR reduction, and that successful repair was associated with lower mortality and heart failure (HF) hospitalizations at one year post-procedure compared with unsuccessful repair.
NEJM: Cerebral Embolic Protection During Transcatheter Aortic-Valve Replacement
A study published today in the New England Journal of Medicine (NEJM) found that among patients with aortic stenosis undergoing transfemoral TAVR, the use of a debris capturing device called cerebral embolic protection reduced the risk of disabling stroke from 1.3% to 0.5%.
New Risk Score Predicts Mortality for Atrial Fibrillation Patients Undergoing Transcatheter Aortic Valve Replacement
Mount Sinai researchers develop new risk stratification tool to optimize patient care and outcomes after TAVR
TVT 2022 Program Now Available
The program for TVT 2022: The Structural Heart Summit is now available online. An annual meeting from the Cardiovascular Research Foundation (CRF), TVT features cutting-edge research and techniques for structural heart interventions and will take place June 8-10, 2022 at the Sheraton Grand Chicago Riverwalk in Chicago, Illinois.
Transcatheter Aortic Valve Replacement is Cost Effective Compared With Surgical Replacement for Low-Risk Patients
An economic analysis of data from PARTNER 3, a randomized trial comparing transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR) in patients with severe aortic stenosis and low surgical risk, found that despite higher procedural costs, at 2-year follow-up, quality-adjusted life expectancy was greater and total costs were lower with TAVR; as a result, at 2-years, TAVR was cost-effective for these patients.
Intermediate-Risk Patients Have Similar Five-Year Outcomes With Transcatheter Or Surgical Aortic Valve Replacement
New five-year data from the SURTAVI trial found that there was no difference in all-cause mortality or stroke between patients at intermediate surgical risk who had transcatheter aortic valve replacement (TAVR) or surgery. Although there were initially more reinterventions after TAVR, the rates were similar after two years and key clinical endpoints were also similar.
Study: Catheter-Based Valve Replacement Helps More Heart Patients
After reviewing national data from nearly 160,000 patients, Cedars-Sinai researchers found that transcatheter aortic valve replacement, or TAVR, could be a favorable option for some low-risk patients with bicuspid aortic stenosis. The findings were published in the Journal of the American Medical Association (JAMA).
Edoxaban May Be Effective Treatment for Atrial Fibrillation After Transcatheter Aortic Valve Replacement
Mount Sinai study is first to compare this anticoagulant with the standard of care in large randomized clinical trial
Late-Breaking Science Announced for TVT 2021
The Cardiovascular Research Foundation (CRF) announced that TVT 2021 will feature 12 studies as Late-Breaking Clinical Science. An annual meeting from CRF, TVT features cutting-edge research and techniques for structural heart interventions. TVT will take place online and in person, with limited attendance, at the Fontainebleau Miami Beach in Miami Beach, Florida July 20-22, 2021.
TVT 2021 Program Now Available
The program for TVT 2021: The Structural Heart Summit is now available online. An annual meeting from the Cardiovascular Research Foundation (CRF), TVT features cutting-edge research and techniques for structural heart interventions. TVT will take place online and in person, with limited attendance, at the Fontainebleau Miami Beach in Miami Beach, Florida July 20-22, 2021.
Mount Sinai Cardiovascular Doctors to Receive Honors During American College of Cardiology 70th Annual Scientific Session
William Whang, MD, Associate Professor of Medicine (Cardiology), and Gilbert Tang, MD, MSc, MBA, Associate Professor of Cardiovascular Surgery at the Icahn School of Medicine at Mount Sinai, are receiving the 2021 Simon Dack Awards for their exceptional contributions to the Journal of the American College of Cardiology (JACC).
Morristown Medical Center Among 1st to Receive American College of Cardiology Transcatheter Valve Certification
Atlantic Health System’s Morristown Medical Center has received American College of Cardiology (ACC) Transcatheter Valve Certification, a designation of excellence that recognizes demonstrated expertise and commitment in treating patients undergoing transcatheter valve repair and replacement procedures, including transcatheter aortic valve replacement (TAVR).
Innovative Mitral Valve Replacement Procedure Shows Promise for High-Risk Patients in Miller School Study
An innovative mitral valve replacement procedure shows promise for high-risk patients in a new University of Miami Miller School of Medicine study led by Joseph Lamelas, M.D., chief and program director of cardiothoracic surgery.
Morristown Medical Center’s Dr. Philippe Généreux Again Named One of World’s Most Highly Cited Researchers
For the second year, Philippe Géneréux, MD, Co-Director of the Structural Heart Program at Atlantic Health System’s Morristown Medical Center and an interventional cardiologist internationally known for his novel research, has been named a Highly Cited Researcher by the Clarivate™ Web of Science™ Group. Dr. Géneréux is the only New Jersey-based physician-scientist to be named to this year’s list in the Clinical Medicine category. Clinical Medicine requires more highly cited papers than any other field to meet the criteria for inclusion on the Highly Cited list.
Free Access to TCT Connect Extended for One Year
All educational programming from TCT Connect will be available to registrants for free through October 18, 2021. TCT is the annual scientific symposium of the Cardiovascular Research Foundation (CRF) and the world’s premier educational meeting specializing in interventional cardiovascular medicine.
Mount Sinai Heart Awarded Transcatheter Valve Certification by American College of Cardiology
Only program in New York City to receive prestigious recognition
Trial Finds that Interventional Closure of Residual Atrial Septal Defect One-Month Post Transcatheter Mitral Valve Repair Was Not Superior to Medical Treatment
The MITHRAS randomized clinical trial found that interventional closure of an iatrogenic atrial septal defect (iASD) driven by transcatheter mitral valve repair (TMVR) was not superior to conservative medical treatment with regard to the primary endpoint of change in six-minute walking distance.
New Bioprosthetic Valve for TAVR Fails to Demonstrate Non-Inferiority
In a randomized clinical trial, SCOPE II, a new self-expanding bioprosthetic valve used in transcatheter aortic valve replacement (TAVR) failed to demonstrate non-inferiority compared to an existing self-expanding valve.
TCT Connect Agenda Now Available
The TCT Connect agenda is now available online. TCT, the annual scientific symposium of CRF and the world’s premier educational meeting specializing in interventional cardiovascular medicine, will take place online October 14-18. Every year, TCT features major medical research breakthroughs and gathers leading researchers and clinicians from around the globe to present and discuss the latest evidence-based research in the field.
Announcing the TCT Connect Late-Breaking Trials and Science
The Cardiovascular Research Foundation (CRF) has announced over 30 late-breaking trial and science presentations that will be reported at TCT Connect. TCT, the annual scientific symposium of CRF and the world’s premier educational meeting specializing in interventional cardiovascular medicine, will take place online October 14-18.
Baylor Scott & White Health Again Recognized as Most Awarded Not-for-profit Health System in Texas by U.S. News & World Report
In the midst of the extraordinary health challenge presented by the COVID-19 pandemic, Baylor Scott & White Health remains committed to quality, safe care and helping Texas communities navigate the uncertainty of the SARS-CoV-2 virus. Today, this commitment to safety and quality is recognized as U.S. News & World Report releases its 2020-2021 Best Hospitals list.
Late-Breaking Science Announced for TVT Connect
The Cardiovascular Research Foundation (CRF) announced that TVT Connect will feature eight studies as Late-Breaking Clinical Science. They will be presented during episodes moderated by the editors of Circulation: Cardiovascular Interventions and JACC: Cardiovascular Interventions. Each late-breaking science episode will host a live wrap-up and Q&A session afterwards.
Medicare Changes May Increase Access to TAVR
The number of hospitals providing TAVR could double with changes to Medicare requirements. Researchers see reason for both excitement and concern.
NEJM: Transcatheter Aortic Valve Replacement Shows Similar Safety Outcomes as Open-Heart Surgery
A new study from the Smidt Heart Institute at Cedars-Sinai and other centers nationwide shows that patients who underwent a minimally invasive transcatheter aortic-valve replacement (TAVR), had similar key 5-year clinical outcomes of death and stroke as patients who had traditional open-heart surgery to replace the valve. The study appears on the New England Journal of Medicine site.
Young Age Does Not Equal Low Risk for Patients Needing Aortic Valve Replacement
While transcatheter aortic valve replacement (TAVR) continues to expand its pool of eligible patients, open heart surgery—resulting in excellent patient survival and fewer strokes when compared to TAVR—is the best option for young and middle-aged adults with aortic valve disease—at least for now.
Cardiothoracic surgeon available for comment on heart valve procedures
Robbin G. Cohen, MD, Associate Professor of Surgery at Keck School of Medicine of the University of Southern California (USC), and Director of the Huntington Memorial Hospital Cardiothoracic and Lung Cancer Surgery Program. He has written extensively and lectured worldwide…
More Heart Valve Patients May Choose Minimally Invasive Procedure
Since August, when the FDA approved a minimally invasive heart valve procedure for an expanded group of patients with aortic stenosis, many more patients are opting for the procedure known as transcatheter aortic valve replacement (TAVR). With this latest approval, the procedure can now be performed on a wide spectrum of patients, from patients too sick to undergo open-heart surgery to those who would be considered low risk for open-heart surgery.
New Self-expanding TAVR Prosthesis Does Not Meet Non-Inferiority Compared to SAPIEN 3
The first randomized trial to compare the safety and efficacy of the new ACURATE neo transcatheter heart valve with the SAPIEN 3 TAVR device did not meet non-inferiority in patients with severe aortic stenosis.
New TAVR System Safe and Effective for High-Risk Surgical Patients with Severe Aortic Stenosis
The Portico IDE study found that 30-day safety and one-year effectiveness outcomes of a novel self-expanding transcatheter aortic valve replacement (TAVR) system for patients with severe aortic stenosis (AS) at high or extreme-risk for surgery was noninferior to contemporary FDA-approved TAVR systems available in the United States.
New Five-Year Data Shows Similar Outcomes for TAVR and SAVR in Patients with Severe Aortic Stenosis and Intermediate Surgical Risk
Five-year results from the PARTNER 2A trial found that patients with severe aortic stenosis (AS) and intermediate surgical risk who underwent transcatheter aortic valve replacement (TAVR) had similar rates of death and disabling stroke compared to those who had surgical aortic valve replacement (SAVR). However, TAVR using a transthoracic approach had poorer outcomes compared to SAVR.
Cardiothoracic surgeon available for comment on FDA’s approval of TAVR for low-risk patients
BIRMINGHAM, Ala. — The FDA announced today the expanded approval for replacement heart valves made by Medtronic and Edwards Lifesciences to include patients at low risk from open-heart surgery. A cardiothoracic surgeon from the University of Alabama at Birmingham is available to provide comment…